




IPW

CASE QA0280 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Joseph C. Wang
Type or print name


Signature

February 8, 2005
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1626

HYNES ET AL.

APPLICATION NO: 10/773,790

FILED: FEBRUARY 6, 2004

FOR: THIAZOLYL BASED COMPOUNDS USEFUL AS KINASE
INHIBITORS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Some of the listed references were cited in a search report in a corresponding PCT International application. Copies of these references and the search report are enclosed herewith.

Also, copies of the other cited references are enclosed herewith.

Applicants bring to the Examiner's attention the following U.S. patent applications and/or patents having co-pendency with the instant application and assigned to the present assignee:

US Publ. No. 2002/0065270A1, published 5/30/02 (Serial No. 09/747,195, filed 12/22/00)

US Publ. No. 2002/0137747A1 (Serial No. 09/891,750, filed 6/26/01)
US Publ. No. 2003/0114504A1 (Serial No. 10/228,544, filed 8/27/02)
US Publ. No. 2004/0024208A1 (Serial No. 10/378,372, filed 3/3/03)
US Publ. No. 2004/0039033A1 (Serial No. 10/315,818, filed 12/10/02)
US Publ. No. 2004/0054186A1 (Serial No. 10/395,503, filed 3/24/03)
US Publ. No. 2004/0073026A1 (Serial No. 10/378,461, filed 3/3/03)
US Publ. No. 2004/0077875A1 (Serial No. 10/378,373, filed 3/3/03)
US application Serial No. 10/970,420, filed 10/21/04

A copy of the specification, drawings and claims as currently pending is attached for each above-identified co-pending application.

PLEASE DO NOT PRINT any of the above information that is not published on any patent resulting from the subject application.


Consideration of each above listed application is earnestly solicited, since unpublished patent applications are contemplated as IDS material; please see 37 CFR §98(a)(2)(iii) and note the last two sentences of MPEP §609 (III)XD).

Further, in keeping with MPEP §609, subsec. (III)(C)(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25), PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent to each above listing so that applicant will know that each listed application has been considered, as required by PTO policy.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-4931


Joseph C. Wang
Attorney for Applicants
Reg. No. 44,391

Date: *February 8, 2005*

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.
QA0280 NP
APPLICATION NO.
10/773,790
APPLICANT
HYNES ET AL.
FILING DATE
FEBRUARY 6, 2004Group
1626

U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						

U.S. PATENT APPLICATION PUBLICATIONS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AB	2002/0065270	5/30/02	Moriarty et al.			
AC	2002/0137747	9/26/02	Moriarty et al.			
AD	2003/0114504	6/19/03	Webster et al.			
AE	2004/0024208	2/5/04	Das et al.			
AF	2004/0039033	2/26/04	Atwal et al.			
AG	2004/0054186	3/18/04	Das et al.			
AH	2004/0073026	4/15/04	Das et al.			
AI	2004/0077875	4/22/04	Das et al.			

U.S. PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AJ	4,200,750	4/29/80	Warner, Jr. et al.			
AK	5,712,279	1/27/98	Biller et al.			
AL	5,739,135	4/14/98	Biller et al.			
AM	5,760,246	6/2/98	Biller et al.			
AN	6,184,231	2/6/01	Hewawasam et al.			
AO	6,262,094	7/17/01	Hoefle et al.			
AP	6,262,096	7/17/01	Kim et al.			
AQ	6,548,529	4/15/03	Robl et al.			
AR	6,596,746	7/22/03	Das et al.			
AS	6,605,599	8/12/03	Vite et al.			
AT	6,706,720	3/16/04	Atwal et al.			

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0280 NP
APPLICATION NO.
10/773,790
APPLICANT
HYNES ET AL.
FILING DATE
FEBRUARY 6, 2004Group
1626

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLAS S	TRANSLATION	
							YES	NO
	2AA	WO 00/62778	10/26/00	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AB	WO 01/10865	2/15/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AC	WO 02/96905	3/8/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AD	WO 01/35959	5/25/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AE	WO 01/70671	9/27/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AF	WO 01/74811	10/11/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	2AG	WO 02/45652	6/13/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>
	AL						<input type="checkbox"/>	<input type="checkbox"/>
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>
	AR						<input type="checkbox"/>	<input type="checkbox"/>
	AS						<input type="checkbox"/>	<input type="checkbox"/>
	AT						<input type="checkbox"/>	<input type="checkbox"/>
	AU						<input type="checkbox"/>	<input type="checkbox"/>
	AV						<input type="checkbox"/>	<input type="checkbox"/>
	AW						<input type="checkbox"/>	<input type="checkbox"/>
	AX						<input type="checkbox"/>	<input type="checkbox"/>
	AY						<input type="checkbox"/>	<input type="checkbox"/>
	AZ						<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
QA0280 NP
APPLICATION NO.
10/773,790
APPLICANT
HYNES ET AL.
FILING DATE
FEBRUARY 6, 2004Group
1626

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	3AA	Ahn, H.-S. et al., "Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity", J. Med. Chem., Vol. 40, No. 14, pp. 2196-2210 (1997)
	3AB	Henry, J.R. et al., "p38 mitogen-activated protein kinase as a target for drug discovery", Drugs of the Future, Vol. 24, No. 12, pp. 1345-1354 (1999)
	3AC	Moreland, L.W. et al., "Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial", Ann. Intern. Med., Vol. 130, No. 6, pp. 478-486 (1999)
	3AD	Rankin, E.C.C. et al., "The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis", British Journal of Rheumatology, Vol. 34, No. 4, pp. 334-342 (1995)
	3AE	Raingaud, J. et al., "MKK3- and MKK6-Regulated Gene Expression Is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway", Molecular and Cellular Biology, Vol. 16, No. 3, pp. 1247-1255 (1996)
	3AF	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases", Current Medicinal Chemistry, Vol. 6, No. 9, pp. 807-823 (1999)
	3AG	Zhao, R. et al., "A new facile synthesis of 2-aminothiazole-5-carboxylates", Tetrahedron Letters, Vol. 42, pp. 2101-2102 (2001)
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.